Clinical Trials Logo

Clinical Trial Summary

In most cases of malignancies, the site of origin of the cancer is clear at presentation or identified soon after. However, Metastatic cancer of unknown primary site (MUO) accounts for 3-5% of all malignant neoplasms, and it is defined as metastatic cancer from an unknown primary site, for which no original site can be detected even after performing all possible tests. Most common metastatic sites include the liver, lymph nodes, lungs, and bones. 18F-fluoro-2-deoxyglucose positron emission tomography (FDG-PET) allows whole-body tumor detection and has proven to be useful in patients with metastasis of unknown primary tumor.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT06086652
Study type Observational
Source Sohag University
Contact Doaa I Mohamed, lecturer
Phone 01007779485
Email doaaibrahim@med.soh.edu.eg
Status Recruiting
Phase
Start date September 15, 2023
Completion date December 2023